Can reactogenicity predict immunogenicity after COVID-19 vaccination?
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background/Aims: This study aimed to assess the association between local and systemic reactogenicity and humoral immunogenicity after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Methods: Adverse events were prospectively evaluated using an electronic diary in 135 healthy adults who received a SARS-CoV-2 vaccine (AZD1222, AstraZeneca/ Oxford, n = 42; or BNT162b2, Pfizer/BioNTech, n = 93). We semi-quantitatively measured anti-S1 immunoglobulin G (IgG) using an enzyme-linked immunosorbent assay at baseline, 3 weeks after the first dose of AZD1222 or BNT162b2, and 2 weeks after the second dose of BNT162b2. We evaluated the association between the maximum grade of local or systemic adverse events and the anti-S1 IgG optical density using multivariate linear regression with adjustment for age, sex, and use of antipyretics. Results: The median age of the 135 vaccinees was 30 years (36 years in the AZD1222 group and 29 years in the BNT162b2 group) and 25.9% were male (9.5% in the AZD1222 group and 33.3% in the BNT162b2 group). Local and systemic adverse events were generally comparable after the first dose of AZD1222 and the second dose of BNT162b2. The grades of local and systemic adverse events were not significantly associated with anti-S1 IgG levels in the AZD1222 or BNT162b2 group. Conclusions: Local and systemic reactogenicity may not be associated with humoral immunogenicity after SARS-CoV-2 vaccination.
Abstract
Background/Aims: This study aimed to assess the association between local and systemic reactogenicity and humoral immunogenicity after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Methods: Adverse events were prospectively evaluated using an electronic diary in 135 healthy adults who received a SARS-CoV-2 vaccine (AZD1222, AstraZeneca/ Oxford, n = 42; or BNT162b2, Pfizer/BioNTech, n = 93). We semi-quantitatively measured anti-S1 immunoglobulin G (IgG) using an enzyme-linked immunosorbent assay at baseline, 3 weeks after the first dose of AZD1222 or BNT162b2, and 2 weeks after the second dose of BNT162b2. We evaluated the association between the maximum grade of local or systemic adverse events and the anti-S1 IgG optical density using multivariate linear regression with adjustment for age, sex, and use of antipyretics. Results: The median age of the 135 vaccinees was 30 years (36 years in the AZD1222 group and 29 years in the BNT162b2 group) and 25.9% were male (9.5% in the AZD1222 group and 33.3% in the BNT162b2 group). Local and systemic adverse events were generally comparable after the first dose of AZD1222 and the second dose of BNT162b2. The grades of local and systemic adverse events were not significantly associated with anti-S1 IgG levels in the AZD1222 or BNT162b2 group. Conclusions: Local and systemic reactogenicity may not be associated with humoral immunogenicity after SARS-CoV-2 vaccination.
참고문헌 (12)
- "WHO coronavirus (COVID-19)dashboard" (2021)[URL]
- Ramasamy MN, "Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults(COV002) : a single-blind, randomised, controlled, phase 2", 3 trial, 2021, pp.396, 1979~1993
- Voysey M, "Safety and efficacy of the ChAdOx1 nCoV-19 vaccine(AZD1222)against SARS-CoV-2 : an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK", Lancet, 397, pp.99~111 (2021)
- Polack FP, "Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine", N Engl J Med, 383, pp.2603~2615 (2020)
- Bae Seongman, "Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea", Journal of Korean Medical Science, 36(17), pp.1~9 (2021), 대한의학회[DOI]
- Burny W, "Different adjuvants induce common innate pathways that are associated with enhanced adaptive responses against a model antigen in humans", Front Immunol, 8, pp.943~ (2017)
- Mitchell TC, "No pain no gain? : adjuvant effects of alum and monophosphoryl lipid A in pertussis and HPV vaccines", Curr Opin Immunol, 47, pp.17~25 (2017)
- "Guidance for industry:toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials" (2007)[URL]
- Choe PG, "Waning antibody responses in asymptomatic and symptomatic SARS-CoV-2 infection", Emerg Infect Dis, 27, pp.327~329 (2021)
- Herve C, "The how’s and what’s of vaccine reactogenicity", NPJ Vaccines, 4, pp.39~ (2019)
- Walsh EE, "Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates", N Engl J Med, 383, pp.2439~2450 (2020)
- Choe PG, "Antibody responses to SARS-CoV-2 at 8 weeks postinfection in asymptomatic patients", Emerg Infect Dis, 26, pp.2484~2487 (2020)